TY - JOUR AU - Küronya, Zsófia AU - Lénárt, Enikő AU - Soós, Edina AU - Géczi, Lajos AU - Bíró, Krisztina TI - Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report JF - JOURNAL OF MEDICAL CASE REPORTS J2 - J MED CASE REP PY - 2026 SN - 1752-1947 DO - 10.1186/s13256-026-05886-3 UR - https://m2.mtmt.hu/api/publication/36983440 ID - 36983440 LA - English DB - MTMT ER - TY - JOUR AU - Budai, Barna AU - Fekete, Bertalan AU - Bíró, Krisztina AU - Lénárt, Enikő AU - Patócs, Attila Balázs AU - Géczi, Lajos TI - A metasztatikus kasztrációrezisztens prosztatarákos betegek abirateronkezelését befolyásoló komorbiditások metaanalízise JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 70 PY - 2026 IS - 1 SP - 53 EP - 68 PG - 16 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/37009547 ID - 37009547 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Powles, Thomas AU - Csőszi, Tibor AU - Loriot, Yohann AU - Matsubara, Nobuaki AU - Géczi, Lajos AU - Cheng, Susanna Y-S AU - Fradet, Yves AU - Alva, Ajjai AU - Oudard, Stéphane AU - Vulsteke, Christof AU - Morales-Barrera, Rafael AU - Fléchon, Aude AU - Gunduz, Seyda AU - Liu, Chih-Chin AU - Moreno, Blanca Homet AU - Bavle, Abhishek AU - Özgüroğlu, Mustafa TI - Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer. Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. TS - Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. JF - CLINICAL GENITOURINARY CANCER J2 - CLIN GENITOURIN CANC VL - 23 PY - 2025 IS - 1 SP - 102261 SN - 1558-7673 DO - 10.1016/j.clgc.2024.102261 UR - https://m2.mtmt.hu/api/publication/35630711 ID - 35630711 N1 - Barts Cancer Centre, Barts Health NHS Trust Biomedical Research Center, Queen Mary University of London, London, United Kingdom County Oncology Centre, Hetényi Géza Hospital, Szolnok, Hungary Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France National Cancer Center Hospital East, Kashiwa, Japan Medical Oncology Center, National Institute of Oncology, Budapest, Hungary Sunnybrook Health Sciences Centre‒Odette Cancer Centre, Toronto, ON, Canada CHU de Québec-Université Laval, Quebec City, QC, Canada Department of Internal Medicine-Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI, United States Georges Pompidou European Hospital, University Paris Cité, Paris, France Department of Medical Oncology, Maria Middelares Hospital, Gent, Belgium Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain Centre Léon Bérard, Lyon, France Department of Medical Oncology, Koc University Hospital, Istanbul, Turkey Merck & Co., Inc., Rahway, NJ, United States Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey Export Date: 15 January 2025 Correspondence Address: Powles, T.; Barts Cancer Centre, Charterhouse Square, EC, United Kingdom; email: thomas.powles1@nhs.net Chemicals/CAS: carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; gemcitabine, 103882-84-4, 95058-81-4; pembrolizumab, 1374853-91-4 AB - KEYNOTE-361 evaluated first-line pembrolizumab with and without platinum-based chemotherapy versus chemotherapy alone in advanced or metastatic urothelial carcinoma. The primary end points of progression-free survival (PFS) or overall survival (OS) were not met. Exploratory analysis of efficacy by platinum agent (cisplatin or carboplatin) is reported.Eligible patients were randomly assigned 1:1:1 to receive pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles with or without chemotherapy (gemcitabine with investigator's choice of either cisplatin or carboplatin) or chemotherapy alone. This exploratory subset analysis evaluated PFS and objective response rate (ORR) per RECIST v1.1 by blinded independent central review and OS for cisplatin- or carboplatin-based chemotherapy with versus without pembrolizumab for patients assigned to chemotherapy-containing arms of KEYNOTE-361.Of 1010 patients enrolled, 703 were assigned to receive a chemotherapy-containing regimen (n = 312 cisplatin based; n = 391 carboplatin based). Median follow-up was 31.3 months. For cisplatin-based arms, with versus without pembrolizumab, median OS was 20.1 versus 16.4 months (HR 0.88, 95% CI, 0.67-1.15) and median PFS was 8.5 versus 7.1 months (HR 0.67, 0.51-0.89). ORR was 64.1% versus 48.7%, respectively. For carboplatin-based arms, with versus without pembrolizumab, median OS was 15.5 versus 12.3 months (HR 0.84, 95% CI, 0.67-1.06) and median PFS was 8.0 versus 6.7 months (HR 0.86, 0.68-1.09). ORR was 47.2% versus 41.8%, respectively. Among patients in the cisplatin-based versus carboplatin-based chemotherapy alone arms, 55.8% versus 41.8% received a subsequent antiprogrammed cell death protein 1/ligand 1 therapy. The addition of pembrolizumab did not significantly increase the incidence of adverse events reported.Results suggest trends toward OS and PFS improvements with the addition of pembrolizumab to gemcitabine-platinum doublet over gemcitabine-platinum alone regardless of whether cisplatin or carboplatin was the chosen platinum agent. OS may have been influenced by active subsequent therapies. LA - English DB - MTMT ER - TY - GEN AU - Géczi, Lajos TI - Terápiás lehetőségek a legfrissebb ajánlások tükrében PY - 2025 UR - https://m2.mtmt.hu/api/publication/36128793 ID - 36128793 LA - Hungarian DB - MTMT ER - TY - GEN AU - Géczi, Lajos TI - Ritka lokalizációjú heredaganat áttétekkel szerzett tapasztalataink PY - 2025 UR - https://m2.mtmt.hu/api/publication/36128816 ID - 36128816 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Polgár, Csaba AU - Tenke, Péter AU - Kiss, András AU - Battyáni, István AU - Kincses, Zsigmond Tamás AU - Györke, Tamás AU - Molnár, Mária Judit AU - Zaletnyik, Zita AU - Hock, Márta AU - Géczi, Lajos AU - Küronya, Zsófia AU - Maráz, Anikó AU - Mangel, László AU - Ágoston, Péter Zoltán AU - Jorgo, Kliton AU - Nyirády, Péter AU - Bajory, Zoltán AU - Szepesváry, Zsolt AU - Melegh, Zsombor AU - Kuthi, Levente AU - Székely, Eszter AU - Borka, Katalin AU - Salamon, Ferenc AU - Gődény, Mária AU - Kalina, Ildikó AU - Korda, Dávid AU - Besenyi, Zsuzsanna AU - Patócs, Attila Balázs AU - Lacsán, Katalin Anna AU - Kapitány, Zsuzsanna AU - Friedrichné, Nagy Andrea TI - A Belügyminisztérium egészségügyi szakmai irányelve a prosztatarák komplex diagnosztikájáról és ellátásáról JF - EGÉSZSÉGÜGYI KÖZLÖNY J2 - EGÉSZSÉGÜGYI KÖZLÖNY VL - 75 PY - 2025 IS - 9 SP - 1006 EP - 1206 PG - 201 SN - 2063-1146 UR - https://m2.mtmt.hu/api/publication/36183013 ID - 36183013 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Küronya, Zsófia AU - Ágoston, Péter Zoltán AU - Jorgo, Kliton AU - Gesztesi, László AU - Kapuvári, Bence AU - Dombovári, P AU - Mavrogenis, Stelios AU - Géczi, Lajos AU - Lénárt, E AU - Dienes, T AU - Manninger, S AU - Szakáll, S AU - Martin, T AU - Bíró, Krisztina TI - Primer staging részeként végzett PSMA PET/CT hatása a klinikai döntésre JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 69 PY - 2025 IS - 2 SP - 203 EP - 207 PG - 5 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/36245367 ID - 36245367 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Géczi, Lajos TI - Aszinkron duplex HER-2-pozitív, előrehaladott emlődaganatos beteg eredményes kezelése tukatinib, transztuzumab, capecitabin kombinált kezeléssel JF - ORVOSTOVÁBBKÉPZŐ SZEMLE J2 - ORVOSTOVÁBBKÉPZŐ SZLE VL - 32 PY - 2025 IS - 11 SP - 63 EP - 66 PG - 4 SN - 1218-2583 UR - https://m2.mtmt.hu/api/publication/36472513 ID - 36472513 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Nagyiványi, Krisztián András AU - Bíró, Krisztina AU - Budai, Barna AU - Dienes, Tamás AU - Gyergyay, Fruzsina AU - Kordáné Horváth, Orsolya AU - Lénárt, Enikő AU - Küronya, Zsófia AU - Pörneczy, Edit AU - Géczi, Lajos TI - Az elsővonalbeli immunterápiával szerzett tapasztalatok az előrehaladott és áttétes vesedaganatos betegek kezelésésben JF - ONKOLÓGIA & HEMATOLÓGIA: AZ ONCOLOGY FOLYÓIRAT MAGYAR NYELVŰ KIADÁSA J2 - ONKOLÓGIA & HEMATOLÓGIA VL - 15 PY - 2025 IS - 6 SP - 356 EP - 364 PG - 9 SN - 2559-8066 UR - https://m2.mtmt.hu/api/publication/36561333 ID - 36561333 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Wheatley, Duncan A AU - Berardi, Rossana AU - Climent Duran, Miguel A AU - Tomiak, Anna AU - Greystoke, Alastair P AU - Joshua, Anthony M AU - Arkenau, Hendrik-Tobias AU - Géczi, Lajos AU - Garcia-Corbacho, Javier AU - Paz-Ares, Luis G AU - Hussain, Syed A AU - Petruželka, Lubos AU - Delmonte, Angelo AU - Chappey, Colombe AU - Masters, Joanna C AU - Michelon, Elisabete AU - Murphy, Danielle A AU - Mwewa, Sandrine AU - Cesari, Rossano AU - Doger de Speville, Bernard TI - First-line avelumab plus chemotherapy in patients with advanced solid tumors. results from the phase 1b/2 JAVELIN Chemotherapy Medley study. TS - results from the phase 1b/2 JAVELIN Chemotherapy Medley study. JF - CANCER RESEARCH COMMUNICATIONS J2 - CANCER RES COMM VL - 4 PY - 2024 IS - 6 SP - 1609 EP - 1619 PG - 11 SN - 2767-9764 DO - 10.1158/2767-9764.CRC-23-0459 UR - https://m2.mtmt.hu/api/publication/34827132 ID - 34827132 N1 - Royal Cornwall Hospital, Treliske, Truro, United Kingdom AOU delle Marche, Università Politecnica delle Marche, Ancona, Italy Instituto Valenciano de Oncología, Valencia, Spain Kingston Health Sciences Centre, Kingston, ON, Canada NU Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia Sarah Cannon Research Institute, HCA Healthcare, London, United Kingdom National Institute of Oncology, Budapest, Hungary Clinic Institute of Hematological and Oncological Diseases, Hospital Clinic, Barcelona, Spain Hospital Universitario 12 de Octubre, Madrid, Spain Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom General University Hospital in Prague, Prague, Czech Republic IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,”, Meldola, Italy Pfizer, San Francisco, CA, United States Pfizer, San Diego, CA, United States Pfizer, New York, NY, United States Pfizer, Paris, France Pfizer, Milan, Italy Fundación Jiménez Díaz University Hospital, Madrid, Spain Export Date: 15 January 2025 Correspondence Address: Wheatley, D.A.; Royal Cornwall Hospital, Treliske, United Kingdom; email: duncanwheatley@nhs.net Chemicals/CAS: avelumab, 1537032-82-8; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; doxecitine, 951-77-9, 56905-41-0; gemcitabine, 103882-84-4, 95058-81-4; pemetrexed, 137281-23-3, 150399-23-8, 357166-30-4, 357166-29-1; Antibodies, Monoclonal, Humanized; avelumab; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Pemetrexed AB - Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase 1b/2 JAVELIN Chemotherapy Medley trial evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or nonsmall cell lung cancer (NSCLC).Avelumab 800 mg or 1200 mg was administered continuously every 3 weeks (Q3W) with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase 1b) and confirmed objective response (phase 1b/2).In phase 1b, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n=13 and n=6, respectively) or 1200 mg (n=6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 mg or 1200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase 2, 35 additional patients with urothelial carcinoma received avelumab 1200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 mg or 1200 mg + chemotherapy, respectively, across phase 1b/2, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC.Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers.gov identifier, NCT03317496. LA - English DB - MTMT ER -